Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Triple defeat puts May’s Brexit deal up against the wall

Prospects of a no-deal Brexit seems to loom ever larger

- PMLiVE

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

Deal centres around blood cancer candidate cusatuzumab

- PMLiVE

Open Health merges with med comms services provider Peloton

The combined entity will fall under the Open Health brand

- PMLiVE

Diagnosed Anywhere

What’s wrong? Increasingly, technology-driven tools have the answer

Live from Singapore: Oncology in APAC – Evaluating the opportunity for novel therapies

Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST

Inizio

- PMLiVE

New hires at Mundipharma, Sinclair Pharma and Relay Therapeutics

Latest movers in pharma

- PMLiVE

Right intervention, right tool

'Don't start with the solution, start with the problem'

- PMLiVE

GSK buys cancer firm Tesaro for $5.1bn

Acquisition re-establishes US commercial operations in oncology

- PMLiVE

Digital applications are transforming the market access landscape

Optimising product value through digital technology

- PMLiVE

Amgen’s BCMA drug on course to challenge CAR-Ts in myeloma

BiTE will rival therapies from Bluebird, Celgene/Juno, J&J/Legend biotech

- PMLiVE

Grail to initiate largest ever UK cancer screening study

Will start testing on 50,000 people in early 2019

- PMLiVE

New models of NHS care – new models of pharma response?

At PME and IQVIA’s roundtable event, leaders discuss how industry needs to adapt to help an NHS undergoing transformational change

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links